PanTum Detect is a CE certified IVD blood test that can detect any cancer at any stage, and which is based on the detection of epitopes in monocytes.

Activated monocytes (macrophages) phagocytose unwanted cells/cell fragments from the whole body, including solid tissues. As they return to the blood, macrophages can be used for non-invasive detection of two biomarkers called Apo10 and TKTL1. This detection provides high sensitivity and specificity because the intracellular presence of biomarkers is due to an innate immune response.

Here’s an overview of over 40 cancer types which were detected in studies using the PanTum Detect tumour markers:

Adenocarcinoma, Aerodigestive Cancer, Astrocytoma, Pancreatic Cancer, Bladder Cancer, Bronchial Cancer, Breast Cancer, Cholangiocarcinoma (Biliary CA), Colorectal Cancer, DIPG / “Pons Gliomas”, Triple Negative Breast Cancer, Ductal Carcinoma, Ovarian Cancer, Endometrial Cancer, Ependymoma, Gastroesophageal Transition Cancer, Cervical cancer, Uterine cancer, Brain tumour, Glioblastoma, Granulosa cell tumour, Gynaecologic cancers, Hepatoblastoma, HER2 positive breast cancer, Hyperplasia, Small cell lung cancer, Head and neck cancer, Lung cancer, Lymphoma tumours, Gastric cancer, Malignant conjunctival tumours, Medulloblastoma, Melanoma tumours, Nasopharyngeal carcinoma, Neoplastic lung tissue, Nephroblastoma, Non-metastatic rectal adenocarcinoma, Non-small cell lung cancer, Renal cancer, Oral squamous cell carcinoma OSCC, Estrogen receptor (ER)-positive breast cancer, Squamous intraepithelial neoplasm (SIN I – III), Squamous cell carcinoma, Squamous cell carcinoma of breast, Squamous cell carcinoma of the prostate, Squamous cell carcinoma of the esophagus (ESCC), Progesterone receptor (PR)-positive breast cancer, Prostate cancer, PSA-positive prostate cancer, PSMA-positive prostate cancer, Rectal cancer, Rhabdomyosarcoma, Thyroid cancer (follicular and papillary), Tumours of the eye appendage, Urothelial cancer, Vaginal cancer, Vulvar cancer

Note: Previously tested lymphomas and leukemias have also shown to be positive for PanTum Detect, but are not included in this list of solid tumours. Disclaimer: This list contains information from publications and information from clinical practice in real testing situations.

PanTum Detect is a pan-cancer test, able to detect all types of cancer but not the variety of cancer that is present. However, the imaging methods such as MRI, PET/CT, offer a high probability of localization and classification of detected tumours.

The biomarkers that are exploited and unique to PanTum are for two fundamental biophysical mechanisms. The DNaseX (Apo10) protein epitope is a characteristic of tumour cells with abnormal apoptosis and proliferation. Transketolase-like 1 (TKTL1) is a marker for an anaerobic glucose metabolism (Warburg effect), which is concomitant with invasive growth/metastasis and resistant to radical and apoptosis-inducing therapies.

Flow cytometry analysis of blood enables the detection of macrophages and phagocytosed intracellular biomarkers. There is an integrated gating and algorithmic analysis within the flow cytometer.

If a customer receives a tumour-suspicious result, a prompt and efficient physician consultation will be organized, and the follow-up examination (such as PET/CT or MRI) and a referral to an oncologist in case the initial suspicion is confirmed.

PanTum Detect is extremely accurate, identifying cancer with 99.05% specificity and 97.5% sensitivity, minimizing the risk of false positives and false negatives.

At present, we are working to make the PanTum Detect test available. We are discussing potential partnerships with clinics across London. Keep an eye on our Twitter and LinkedIn page and website for updates on when the PanTum Detect + Imaging Screening Program will be available.

This is great news! No immediate further test is required. We recommend that you schedule another PanTum Detect test within 12 months to provide ongoing peace of mind.

PanTum Detect is a simple blood test that measures two markers within your immune system. If the markers pass a certain threshold, the test result is tumour suspicious.

No, PanTum Detect is performed in exactly the same way as a regular blood draw.

It usually takes around a week to get the results of PanTum Detect.

No, PanTum Detect can only detect the presence of cancerous cells. However, this can support the diagnosis of any type of suspected cancer, especially if the symptoms you have been experiencing are very mild or inconclusive. Imaging methods such as MRI, PET/CT, offer a high probability of localization and classification of detected tumours.

Yes, PanTum Detect is able to indicate whether your cancer is likely to be early or late stage. This is thanks to the markers it detects. One marker indicates early-stage cancer, while the other is only present in later stage cancers.

The cost of PanTum Detect is comparative with the cost of other biomarker tests available in the market. Our partner clinics can give you further information on pricing.

PanTum Detect would be a great addition to any regular health monitoring and we recommend patients have the test at least once per year. This will help ensure that any cancer that may develop is detected at the earliest possible opportunity.

No, there is no age limit. PanTum Detect can be successfully used to detect cancer in people of any age.

If you receive a tumour-suspicious result, a prompt and efficient physician consultation will be organized, and the follow-up examination (such as PET/CT or MRI) and a referral to an oncologist in case the initial suspicion is confirmed.

Currently, the test is not available for appointments.  We hope to be working with clinics and oncology centres in London and across the UK soon. PanTum Detect will also shortly be available at our global partner clinics in the Middle East. For a full list of RMDM’s diagnostic territories, please keep an eye on our Diagnostics page for updates.